Adoptive T Cell Therapy Technology

Geneius is a Bio-Pharmaceutical Company focused on the discovery and clinical development of adoptive T cell therapy products that address the treatment of cancer and infections.

Targeted DiversiTy™ T CELLS

We are developing an autologous, adoptive cell therapy technology which is designed to selectively unleash the patient’s immune response to cancer.  Geneius’ Targeted DiversiTy™ platform re-educates the patient’s own T cells to be responsive to overlooked antigens to deliver a specific and durable immune response that we believe is less susceptible to tumor immune evasion. Learn More…